Skip to main content

Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark

    Basic Details
    Friday, August 26, 2022

    This poster examines the trends of Angiotensin-Receptor-Blocker (ARB) utilization and switching patterns in the U.S., Canada, and Denmark, before and after July 2018, when the first ARB (Valsartan) was recalled. It was presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. 


    Eworuke E., Shinde M., Hou L., Paterson M., Jensen P., Maro JC., Rai A., Scarnecchia D., Dinci P., Woronow D., Ghosh RE., Welburn S., Pottegård A., Platt RW., Lee H., Bradley MC.